Replies to post #46901 on NorthWest Biotherapeutics Inc (NWBO)

[Smokey21]

I'm sorry, but there is way too many cloak & dagger discussions going on here. We are clearly under attack, but it is not from Woodford. His MO and his actions to-date don't even hint at that possibility. Not saying Ondra couldn't be implicated in some way, but they are not doing Woodford's bidding.

I think it is unfair to accuse Woodford of underhanded attempts. He was buying the stock in the open market, right up until 12. What possible reason could he have to do that, then drive it down to 4 and pay a premium at $5.50 on the last financing. He is a stand-up guy in my opinion, and the shorts have put him in a bad position as well and their only hope is that he starts to sell some of his 25 million shares so they can start covering their 13 million share short position (plus some level of naked shorts).

[CherryTree1]

I looked quick and it looks like NW's involvement was not a well planned take over attempt. It appears like he got involved to try to help protect/save his investment as may well too be the case with NWBO.

Also this was back in the 2008-2010 time frame. Just eyeballing it quickly the stock price (OIH) looks to have oscillated around $50, lows around $25 and highs around $70, but hard looking at this to attribute a well planned NW take over as the downfall of the company, wouldn't you agree?

http://www.telegraph.co.uk/finance/comment/richardfletcher/8969322/Omega-Insurance-is-a-thorn-in-Neil-Woodfords-portfolio.html

As I noted back in 2008, Woodford invested in a string of Aim-listed
tiddlers brought to the market at the height of the credit bubble by Cenkos – despite his focus on income funds.
The decision to take sizable stakes in the illiquid Aim flotations left rival fund managers puzzled at the time. So unusual were the investments that a number of companies in which Invesco invested were forced to list the fund manager's influence as a "risk factor".
Like many of the smaller companies on the Aim market, many of the Cenkos flotations are now trading at substantial discounts to their float price – but few have caused Woodford as much hassle
as Omega.
Woodford has become increasingly embroiled in every twist and turn at Omega over the past two years. The fund manager led the ousting of the Omega board in 2010, with the (controversial) assistance of Cenkos – the insurer's own City advisers.
Back in October he appeared to have finally brought the sorry tale to a close, when he effectively backed Byrne's
83p-a-share tender offer in preference to a rival cash offer and a separate nil-premium merger. Unfortunately, he hadn't counted on Byrne getting cold feet.
Woodford is now stuck between a rock and a hard place. Worth just £43.5m, Woodford's stake in Omega is little more than a rounding error given the size of his funds. No doubt the fund manager – and his investors – would rather he focused his time and efforts on those companies that could actually have an effect on his funds' performance.
The star fund manager must now rue the day he invested in Omega.